Newer long-term treatments for multiple sclerosis.
Pryse-Phillips
William
W
Department of Neurology, Health Sciences Center, Memorial University of Newfoundland, 300 Prince Phillip Parkway, St. John's, Canada NF A1B 3V6. wpryse@mun.ca
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000917:Antibody Formation; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D004992:Ethics, Medical; D000068717:Glatiramer Acetate; D017048:Health Care Costs; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D010455:Peptides / Q000627:therapeutic use*; D010956:Plasmapheresis; D011379:Prognosis; D011788:Quality of Life; D012008:Recurrence
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a